'Possible Link' Found Between AstraZeneca COVID-19 Vaccine, Rare Blood Clots
WEDNESDAY, April 7, 2021 -- There is a "possible link" between the AstraZeneca COVID-19 vaccine and rare blood clots, but the benefits of the vaccine still outweigh the risks, the European Union drug regulator says.
Some countries have placed new age restrictions on use of the vaccine in people 18 years and older, but the European Medicines Agency decided not to, the Associated Press reported.
Agency experts reviewed several dozen cases, mainly from Europe and the United Kingdom, and determined that such clots are "very rare" side effects of the vaccine that occur mainly in women younger than 60 years within two weeks of getting the shot. No specific risk factors could be pinpointed, the AP reported.
"The reported cases of unusual blood clotting following vaccination with the AstraZeneca vaccine should be listed as possible side effects of the vaccine," according to Emer Cooke, the agency's executive director, who added that the "risk of mortality from COVID is much greater than the risk of mortality from these side effects."
© 2021 HealthDay. All rights reserved.
Posted: April 2021
Further Support and Information on COVID-19
Read this next
FRIDAY, April 9, 2021 -- Blood type is not associated with COVID-19 susceptibility or outcomes, according to a research letter published online April 5 in JAMA Network...
FRIDAY, April 9, 2021 -- Antibodies persist through six months after the second dose of the Moderna COVID-19 mRNA vaccine, according to a letter to the editor published online...
FRIDAY, April 9, 2021 -- Patients undergoing dialysis and those with kidney transplants had increased mortality risk in 2020 compared with 2017 to 2019, according to a study...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.